VIENTIANE, VIENTIANE, LAO PDR, July 28, 2023 — The Lao Food and Drug Administration has conducted an inspection and guidance visit to the Traditional Chinese Medicine (TCM) Production Facility of Big Bear Pharma.
The investor team of Big Bear Pharma went to Laos in 2021 to assess the local investment environment, and officially launched the construction of production facilities in the same year. After nearly one year of construction and refinement, the company’s TCM Production Facility has welcomed the first inspection by the Lao Food and Drug Administration.
This inspection by the Lao Food and Drug Administration has provided constructive guidance for Big Bear Pharma to further upgrade its TCM production standards and establish standardized production protocols going forward.
The CEO of Big Bear Pharma stated, “We are delighted to host the inspection by the Ministry of Health. This visit marks a crucial step for the company. With the support of our investors and all employees, we will continue to build and improve the relevant facilities and standards for TCM production. This is a path quite different from what we have taken before, but we will always adhere to innovation and exploration.”
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to the development and commercialization of innovative cancer therapies. The company boasts a diversified pipeline of anti-cancer targeted drugs that target various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of cancer patients by providing them with more treatment options, better clinical outcomes and lower treatment costs.
Forward-Looking Statements
Within the scope permitted by applicable laws and regulations, statements containing words such as “plan”, “target”, “expect” and “forecast” in this press release are forward-looking statements. The forward-looking statements made herein are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated. Key factors contributing to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties regarding clinical research results, various market risks, as well as other factors beyond the company’s control.
